Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi

Frontiers in Cellular and Infection Microbiology

Cellular and Infection Microbiology

Yuemei Wang¹  Lei Li¹  Gengpei Jia²  Lianjuan Yang³  Jingwen Tan³  Lulu An³ 

[1] Department of Clinical Laboratory, Shibei Hospital, Shanghai, China;Department of General Medicine, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China;Department of Medical Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China;

关键词: everolimus;    synergistic effect;    chromoblastomycosis;    antifungal;    dematiaceous fungi;   

DOI  :  10.3389/fcimb.2023.1131416

 received in 2022-12-25, accepted in 2023-02-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionChromoblastomycosis (CBM) is a form of chronic mycosis that affects the skinand mucous membranes and is caused by species of dematiaceous fungi including Exophiala spp., Phialophora spp., and Fonsecaea spp. The persistence of this disease and limitations associated with single-drug treatment have complicated efforts to adequately manage this condition.MethodsIn this study, a microdilution assay was used to explore the synergistic antifungal activity of everolimus (EVL) in combination with itraconazole (ITC), voriconazole (VRC), posaconazole (POS), and amphotericin B (AMB) against a range of clinical dematiaceous fungal isolates.ResultsThese analyses revealed that the EVL+POS and EVL+ITC exhibited superior in vitro synergistic efficacy, respectively inhibiting the growth of 64% (14/22) and 59% (13/22) of tested strains. In contrast, the growth of just 9% (2/22) of tested strains was inhibited by a combination of EVL+AMB, and no synergistic efficacy was observed for the combination of EVL+VRC.DiscussionOverall, these findings indicate that EVL holds promise as a novel drug that can be synergistically combined with extant antifungal drugs to improve their efficacy, thereby aiding in the treatment of CBM.

【 授权许可】

Unknown   
Copyright © 2023 An, Jia, Tan, Yang, Wang and Li